Third-generation drug-eluting stent now available in CE Mark countries
Nov. 2, 2009 (PR Newswire) --
NATICK, Mass., Nov. 2 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark for its PROMUS® Element(TM) Everolimus-Eluting Coronary Stent System, the Company's third-generation drug-eluting stent (DES) technology. The PROMUS Element system incorporates a unique platinum chromium alloy with an innovative stent design and an advanced catheter delivery system.
To view the Multimedia News Release, go to: http://multivu.prnewswire.com/mnr/bostonscientific/36501/
(Photo: http://www.newscom.com/cgi-bin/prnh/20091102/NY02934 )
The Company will begin marketing the PROMUS Element system immediately in the European Union and other CE Mark countries. CE Mark was granted by the Dutch Notified Body KEMA Quality B.V.
The platinum chromium alloy used in the PROMUS Element stent is engineered specifically for coronary stenting. This proprietary alloy offers greater radial strength and flexibility than older alloys such as the cobalt chromium alloy used in the XIENCE PRIME(TM) DES, and it provides enhanced visibility and reduced recoil. The innovative stent design improves deliverability and allows for more consistent lesion coverage and drug distribution. The advanced catheter delivery system further improves deliverability.
"The platinum chromium alloy and new stent design used in the PROMUS Element stent represent significant innovations in drug-eluting stent technology," said Bruno Farah, M.D., Clinique Pasteur, Toulouse, France. "In my experience, the Element platform offers a stenting option that provides superior deliverability and visibility with excellent comformability and low recoil. I believe it offers performance improvements that could simplify procedures and allow treatment of a broader range of patients."
In addition to the PROMUS Element Everolimus-Eluting Coronary Stent System, the Company plans to offer the TAXUS® Element(TM) Paclitaxel-Eluting Coronary Stent System. Both Element systems incorporate the platinum chromium alloy with the innovative stent design and advanced catheter delivery system.
"We are proud to introduce our third-generation drug-eluting stent to physicians and patients in Europe and other CE Mark countries," said David McFaul, Boston Scientific Senior Vice President, International. "The PROMUS Element system is the latest example of Boston Scientific's commitment to DES market leadership and continued innovation. We also plan to launch the TAXUS Element system in CE Mark countries next year, giving physicians the choice of two proven drug and polymer combinations - used in millions of patients worldwide - on an entirely new stent platform.
